Skip to main content
Rigontec purchased by Merck for $554M
9/7/2017

Rigontec was acquired by Merck for up to $554 million. The deal will expand Merck's cancer immunotherapy franchise using Rigontec's technology that activates retinoic acid-inducible gene I, which induces immediate and long-term antitumor immunity.

Full Story: